Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 12/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | PRKACA | P17612 | 5/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24434822 | 0.91 | MAPT (0.48) | ROCK1ROCK2ALDH1A1MAPTTHRB | |
| SCHEMBL24434607 | 0.88 | KDM4E (0.47) | ROCK1ROCK2MAPTRAB9AHTT | |
| SCHEMBL24435120 | 0.87 | AOC3 (0.45) | ALDH1A1MAPK1RAB9AHTTNPC1 | |
| SCHEMBL24434861 | 0.86 | AOC3 (0.48) | ROCK1PRKACAROCK2ALDH1A1MAPK1 | |
| SCHEMBL24435128 | 0.84 | ROCK2 (0.43) | ROCK1ROCK2ALDH1A1MAPTRAB9A | |
| SCHEMBL24435332 | 0.84 | RXFP1 (0.47) | ROCK1ROCK2ALDH1A1MAPK1RAB9A | |
| SCHEMBL24434604 | 0.83 | SCN3A (0.49) | ROCK1ROCK2 | |
| SCHEMBL24434622 | 0.83 | SMN1; SMN2 (0.43) | ALDH1A1MAPTMAPK1RAB9AHTT | |
| SCHEMBL24434817 | 0.83 | SCD (0.47) | ALDH1A1MAPTMAPK1RAB9AHTT | |
| SCHEMBL31466389 | 0.82 | ALDH1A1 (0.46) | ROCK1CYP3A4PRKACAROCK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | ROCK1 2147/4885CYP3A4 3223/4885PRKACA 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.